Payment overview · 2025
General Payments
$627.48
35 reported records · 11 companies
Healthcare provider profile · identity verified
Richard E Vasicek, DO
Allopathic & Osteopathic Physicians|Family Medicine · FAIRMONT, WV · NPI 1316037146
Verified facts
What the public records show
CMS Open Payments records show Richard E Vasicek, DO received $627.48 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $286.84 | 45.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.76 | 10.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.45 | 9.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.77 | 7.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.72 | 4.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.13 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.80 | 4.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.73 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.25 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.30 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.73 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.48 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $158.46 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.90 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.90 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.76 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.76 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
248 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 837 | 161 |
| Omeprazole | Omeprazole | 554 | 82 |
| Lisinopril | Lisinopril | 550 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 432 | 76 |
| Furosemide | Furosemide | 405 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 340 | 43 |
| Metformin Hcl | Metformin Hcl | 315 | 59 |
| Sertraline Hcl | Sertraline Hcl | 284 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 280 | 39 |
| Famotidine | Famotidine | 258 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 45 |
| Eliquis | Apixaban | 248 | 30 |
| Gabapentin | Gabapentin | 233 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 224 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 42 |
| Potassium Chloride | Potassium Chloride | 177 | 46 |
| Levetiracetam | Levetiracetam | 164 | suppressed |
| Losartan Potassium | Losartan Potassium | 153 | 41 |
| Allopurinol | Allopurinol | 152 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 44 |
| Trazodone Hcl | Trazodone Hcl | 147 | 28 |
| Mirtazapine | Mirtazapine | 145 | 31 |
| Alprazolam | Alprazolam | 138 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 32 |
| Montelukast Sodium | Montelukast Sodium | 129 | 35 |
| Memantine Hcl | Memantine Hcl | 127 | 12 |
| Ezetimibe | Ezetimibe | 124 | 31 |
| Spironolactone | Spironolactone | 120 | 17 |
| Xarelto | Rivaroxaban | 120 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 37 |
| Donepezil Hcl | Donepezil Hcl | 117 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 25 |
| Simvastatin | Simvastatin | 114 | 26 |
| Prednisone | Prednisone | 109 | 72 |
| Buspirone Hcl | Buspirone Hcl | 108 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 107 | 14 |
| Carvedilol | Carvedilol | 97 | 25 |
| Meloxicam | Meloxicam | 97 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 12 |
| Januvia | Sitagliptin Phosphate | 92 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 61 |
| Warfarin Sodium | Warfarin Sodium | 78 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 12 |
| Primidone | Primidone | 74 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 74 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 18 |
| Finasteride | Finasteride | 70 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 69 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 64 | suppressed |
| Glipizide | Glipizide | 63 | 15 |
| Enulose | Lactulose | 61 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 27 |
| Jardiance | Empagliflozin | 60 | 19 |
| Amoxicillin | Amoxicillin | 59 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 48 |
| Enalapril Maleate | Enalapril Maleate | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Metformin Hcl Er | Metformin Hcl | 45 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Cephalexin | Cephalexin | 42 | 29 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Naproxen | Naproxen | 32 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 19 |
| Atenolol | Atenolol | 29 | 12 |
| Fluconazole | Fluconazole | 29 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Perphenazine | Perphenazine | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Cimetidine | Cimetidine | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 19 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Methimazole | Methimazole | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | 11 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $627.48 · 35 records | Novo Nordisk Inc | Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error